Tumor-specific fluorescent antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer

Hepato-Gastroenterology

Volumn 59, Issue 118, 2012, Pages 1994-1999

  Tran Cao, Hop S ^a   Kaushal, Sharmeela ^a   Metildi, Cristina A ^a   Menen, Rhiana S ^a,b   Lee, Claudia ^c   Snyder, Cynthia S ^a   Messer, Karen ^a   Pu, Minya ^a   Luiken, George A ^d   Talamini, Mark A ^a   Hoffman, Robert M ^a,e   Bouvet, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UVP LLC   (United States)

^d OncoFluor Inc   (United States)

^e ANTICANCER INC   (United States)

Author keywords

CEA; Fluorescence; Laparoscopy; Pancreatic cancer; Staging

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CARCINOMATOSIS; CONTROLLED STUDY; FEMALE; FLUORESCENCE IMAGING; FLUORESCENT ANTIBODY TECHNIQUE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; LAPAROSCOPY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; ANIMAL; IMMUNOLOGY; METASTASIS; METHODOLOGY; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TIME; TUMOR CELL LINE;

CARCINOEMBRYONIC ANTIGEN; DIAGNOSTIC AGENT; FLUORESCENT DYE; MONOCLONAL ANTIBODY;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FLUORESCENT DYES; HUMANS; LAPAROSCOPY; MICE; MICE, NUDE; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84866427767     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11836     Document Type: Article

References (22)

1. Jimenez RE, Warshaw AL, Rattner DW, et al.: impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg 2000; 135:409-414 (discussion 414-405).
2. Verbeke CS: Resection margins and R1 rates in pancreatic cancer - are we there yet? Histopathology 2008; 52:787-796.
3. Nguyen QT, Olson ES, Aguilera TA, et al.: Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci USA 2010; 107:4317-4322.
4. Kishimoto H, Kojima T, Watanabe Y, et al.: In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med 2006; 12:1213-1219. (Pubitemid 44527360)
5. Kishimoto H, Zhao M, Hayashi K, et al.: In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci USA 2009; 106:14514-14517.
6. McElroy M, Kaushal S, Luiken GA, et al.: Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated anti-CA19-9 antibody for surgical navigation. World J Surg 2008; 32:1057-1066.
7. Urano Y, Asanuma D, Hama Y, et al.: Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 2009; 15:104-109.
8. Hu CM, Kaushal S, Tran Cao HS, et al.: Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm 2010; 7:914-920.
9. Erten A, Wrasidlo W, Scadeng M, et al.: Magnetic resonance and fluorescence imaging of doxorubicin-loaded nanoparticles using a novel in vivo model. Nanomedicine 2010; 6:797-807.
10. Reichert JM, Valge-Archer VE: Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6:349-356. (Pubitemid 46696550)
11. Waldmann TA, Levy R, Coller BS: Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. Hematology Am Soc Hematol Educ Program 2000:394-408.
12. Albers GH, Fleuren G, Escribano MJ, Nap M: Immunohistochemistry of CEA in the human pancreas during development, in the adult, chronic pancreatitis and pancreatic adenocarcinoma. Am J Clin Pathol 1988; 90:17-22.
13. Yamaguchi K, Enjoji M, Tsuneyoshi M: Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol 1991; 47:148-154.
14. Kaushal S, McElroy MK, Luiken GA, et al.: Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J Gastrointest Surg 2008; 12:1938-1950.
15. Conlon KC, Dougherty E, Klimstra DS, et al.: The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg 1996; 223:134-140. (Pubitemid 26065205)
16. Tran Cao HS, Kaushal S, Lee C, et al.: Fluorescence laparoscopy imaging of pancreatic tumor progression in an orthotopic mouse model. Surg Endosc 2011; 25:48-54.
17. Tran Cao HS, Kaushal S, Menen RS, et al.: Submillimeter-resolution fluorescence laparoscopy of pancreatic cancer in a carcinomatosis mouse model visualizes metastases not seen with standard laparoscopy. J Laparoendosc Adv Surg Tech A 2011; 21:485-489.
18. Kelly KJ, Wong J, Gladdy R, et al.: Prognostic impact of RT-PCR-based detection of peritoneal micrometastases in patients with pancreatic cancer undergoing curative resection. Ann Surg Oncol 2009; 16:3333-3339.
19. Winer JH, Choi HS, Gibbs-Strauss SL, et al.: Intraoperative localization of insulinoma and normal pancreas using invisible near-infrared fluorescent light. Ann Surg Oncol 2010; 17:1094-1100.
20. Stiles BM, Bhargava A, Adusumilli PS, et al.: The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery 2003; 134:357-364. (Pubitemid 37070361)
21. Gahlen J, Prosst RL, Pietschmann M, et al.: Laparoscopic fluorescence diagnosis for intraabdominal fluorescence targeting of peritoneal carcinosis experimental studies. Ann Surg 2002; 235:252-260. (Pubitemid 34111955)
22. Loning M, Diddens H, Kupker W, Diedrich K, Huttmann G: Laparoscopic fluorescence detection of ovarian carcinoma metastases using 5-aminolevulinic acid-induced protoporphyrin IX. Cancer 2004; 100:1650-1656. (Pubitemid 38456342)